Q-omics provides the consensus-scored CDK3 profile across patient tissues and cancer cell-line models. CDK3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CDK3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CDK3 RNA expression shows 18,788 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where CDK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDK3 survival associations across molecular data types. CDK3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDK3 RNA expression–survival associations across cancer types. High CDK3 expression shows unfavorable associations in ACC, KIRC, KICH and COAD, but favorable associations in HNSC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CDK3 RNA expression.
This table summarizes CDK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CDK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDK3 shows lower tumor expression in BRCA and KICH and higher tumor expression in KIRC, LIHC, BLCA and CHOL. The KIRC box plot shows higher CDK3 RNA expression in tumor versus normal tissue (log2 FC = +0.334, t-test p < 0.001).
This table shows molecular features associated with CDK3 in patient tissues and cancer cell lines. In patient samples, CDK3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
